@article{acac4aeab3894c26ae56e09646a4d6da,
title = "Corrigendum: PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma",
author = "Annalisa D'Avola and Nathalie Legrave and Myl{\`e}ne Tajan and Probir Chakravarty and Shearer, \{Ryan L.\} and King, \{Hamish W.\} and Katarina Kluckova and Cheung, \{Eric C.\} and Clear, \{Andrew J.\} and Gunawan, \{Arief S.\} and Lingling Zhang and James, \{Louisa K.\} and MacRae, \{James I.\} and Gribben, \{John G.\} and Calado, \{Dinis P.\} and Vousden, \{Karen H.\} and Riches, \{John C.\}",
note = "Acknowledgments The authors are very grateful to all of the patients who generously donated their tissue to the tissue biobank. We also thank Kamil Kranc for his thorough review of the manuscript. In addition, we thank Riken for the B6;129P2-Phgdh<tm2Bsi> (Phgdh fl ) mice and Raze Therapeutics for providing PH-755. This work was supported by fellowships and grants from the Wellcome Trust (110020/Z/15/Z to JCR; 213555/Z/18/Z to HWK) and Cancer Research UK (C596/A26855 to KHV). In addition, this work was supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001557, FC001057), the United Kingdom Medical Research Council (FC001557, FC001057), and the Wellcome Trust (FC001557, FC001057), and by Barts Cancer Institute, which receives funding from a Cancer Research UK Centre Grant (C355/A25137). For the purpose of open access, the authors have applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission",
year = "2024",
month = feb,
day = "15",
doi = "10.1172/JCI179917",
language = "English",
volume = "134",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "American Society for Clinical Investigation",
number = "4",
}